eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank

vol. 16
Letter to the Editor

Association between myeloperoxidase rs2333227 polymorphism and susceptibility to coronary heart disease

Yi-Qing Zhang
Yu-Feng Jiang
Min Chen
Nan-Nan Zhang
Ya-Feng Zhou

Department of Cardiology, the First Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province, P.R. China
Arch Med Sci 2020; 16 (5): 1231–1238
Online publish date: 2020/05/27
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Coronary heart disease (CHD) accounts for the most morbidity and mortality all over the world [1]. Heritable factors account for 30–60% of the susceptibility to coronary heart disease, and therefore genotypic variants are potential modifiers of predisposition to coronary heart disease. Our previous study demonstrated that apolipoprotein A1 polymorphism was associated with coronary artery disease [2]. Recently, researchers have revealed myeloperoxidase (MPO) as a new potential mutation associated with the pathogenesis of CHD [3]. In Piedrafita et al.’s study, MPO rs2333227 was reported to be associated with significantly decreased transcriptional activity due to the disruption of an SP1 (speci­ficity protein-1)-binding site in an Alu hormone-responsive element [4]. To date, there have been many researchers studying the association between MPO rs2333227 and coronary heart disease. But the results were not consistent. Given the conflicting evidence on this issue, we conducted the present meta-analysis of all available studies to evaluate the association between MPO rs2333227 genetic polymorphism and the risk of coronary heart disease.
We performed our meta-analysis according to the “Meta-analysis Of Observational Studies in Epidemiology” (MOOSE) proposal [5]. To identify eligible studies for this meta-analysis, two investigators (Yi-Qing Zhang and Yu-Feng Jiang) searched the PubMed, Web of Science, Embase, CNKI (Chinese National Knowledge Infrastructure) and WanFang database in all languages up to March 31, 2017, combined with a manual search of reference lists from identified studies. For the article search, the following combination of medical subject heading or suitable key words was used: coronary heart disease, coronary artery disease, ische­mic heart disease, angina or myocardial infarction and myelope­roxidase rs2333227 and polymorphism. The inclusion criteria were pre-established: 1) case-control designed studies; 2) studies that evaluated the association of myeloperoxidase polymorphism and susceptibility to CHD; 3) provided detailed information on genotype frequency and 4) studies that provided sufficient data to calculate odds ratios (ORs) and 95% confidential intervals for extraction. Useful data in all eligible studies were extracted by two authors (Yi-Qing Zhang and Yu-Feng Jiang). Conflicts were discussed with a third investigator (Ya-Feng Zhou). Study quality was assessed according to the 9-point Newcastle-Ottawa Scale (NOS)...

View full text...
Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe